# GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

> **NCT05632354** · PHASE2,PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 47 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Osivelotor

## Key facts

- **NCT ID:** NCT05632354
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-05
- **Primary completion:** 2025-02-13
- **Final completion:** 2025-02-13
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Study terminated as data obtained from this non-placebo-controlled trial may not be informative for the interpretation of the benefits and risks of osivelotor
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05632354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05632354, "GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05632354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*